Study reveals synergistic effect of CDK2 and CDK4/6 combination therapy
This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use
These findings are notable because several CDK2 inhibitor candidates are currently making their way to clinical trials
This combination treatment targets two types of breast cancer that currently have limited treatment options
A new preclinical study from researchers at The University of Texas MD...
Engineered nanobodies improved respiratory defenses in preclinical study
There are no current therapies designed to improve protection against multiple different respiratory viruses
Engineered nanobodies improved...
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
Lynch Syndrome significantly increases the lifetime risk of developing multiple cancers, including colorectal and endometrial
NOUS-209...
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained cancer free
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies – brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine...
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
Linavonkibart, also known as SRK-181, is an experimental therapy from Scholar Rock that aims to prevent or overcome resistance to immune checkpoint...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and not the type, of bacteria inside tumors can predict response to treatment in lab...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Researchers identify novel therapeutic target to improve recovery after nerve injury
Peripheral nerve injury reduces the ability of macrophages to clear dead or dying cells – a process known as efferocytosis – leading to chronic...
High levels of protein drive tumor immune suppression in head and neck cancer
BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment
Glutamine...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study...
Circadian rhythms may affect risk of bacterial infection
Researchers identified an inflammation biomarker in laboratory model that predicts which individuals are at an increased risk of bacterial infection...